Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Candel Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 71 | 1 | 82 | +12 |
| Shares | 18.0M | 68.2K | 21.2M | +3.31M (+18.5%) |
| Value | $155.7M | $592.2K | $119.7M | −$35.4M (−22.8%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (24)
Institutions that held Candel Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 234,597 | $1.33M | 0.00% |
| Franklin Resources Inc | 211,014 | $1.19M | 0.00% |
| Nuveen, LLC | 78,145 | $441.5K | 0.00% |
| Moneta Group Investment Advisors LLC | 38,869 | $219.6K | 0.00% |
| Balyasny Asset Management LLC | 37,710 | $213.1K | 0.00% |
| Intech Investment Management LLC | 28,566 | $161.4K | 0.00% |
| Stratos Wealth Advisors, LLC | 23,000 | $129.9K | 0.01% |
| Raymond James Financial Inc | 22,650 | $128.0K | 0.00% |
| Axq Capital, LP | 19,943 | $112.7K | 0.05% |
| EntryPoint Capital, LLC | 17,907 | $101.2K | 0.05% |
| Price T Rowe Associates Inc | 12,275 | $70.0K | 0.00% |
| Mariner, LLC | 11,371 | $64.2K | 0.00% |
| Quest Partners LLC | 10,870 | $61.4K | 0.01% |
| Creative Planning | 10,742 | $60.7K | 0.00% |
| Invesco Ltd. | 10,413 | $58.8K | 0.00% |
| Private Advisor Group, LLC | 10,350 | $58.5K | 0.00% |
| Taylor Financial Group, Inc. | 10,000 | $56.5K | 0.04% |
| Jones Financial Companies LLLP | 456 | $2.71K | 0.00% |
| US Bancorp | 416 | $2.35K | 0.00% |
| UMA Financial Services, Inc. | 76 | $430 | 0.00% |
| Allworth Financial LP | 45 | $225 | 0.00% |
| Signaturefd, LLC | 39 | $220 | 0.00% |
| EverSource Wealth Advisors, LLC | 38 | $215 | 0.00% |
| True Wealth Design, LLC | 8 | $46 | 0.00% |
Sold out (12)
Institutions that held Candel Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Braidwell LP | 1,600,000 | $13.9M |
| Bridgeway Capital Management, LLC | 77,195 | $670.1K |
| Maven Securities LTD | 51,731 | $449.0K |
| Oppenheimer & Co Inc | 37,915 | $329.1K |
| Heights Capital Management, Inc | 30,000 | $260.4K |
| Kovitz Investment Group Partners, LLC | 20,000 | $173.6K |
| Vontobel Holding Ltd. | 19,000 | $164.9K |
| Jane Street Group, LLC | 16,572 | $143.8K |
| Oxford Asset Management LLP | 12,003 | $104.2K |
| Transform Wealth, LLC | 11,577 | $100.5K |
| LPL Financial LLC | 10,703 | $92.9K |
| Ikarian Capital, LLC | 1,400 | $12.2K |
Not filed for Q1 2025 yet (1)
Institutions that held Candel Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 68,226 | $592.2K |